DexCom Q3 2024 Earnings Report
Key Takeaways
Dexcom's Q3 2024 revenue grew by 2% year-over-year to $994.2 million. The company launched Stelo, a new biosensor for adults with prediabetes and type 2 diabetes, and advanced its international product portfolio with Dexcom G7 and Dexcom ONE+ launches. The company is reiterating its fiscal year 2024 revenue guidance of approximately $4.00 - 4.05 billion.
Revenue grew 2% year-over-year to $994.2 million.
U.S. revenue declined 2%, while international revenue grew 12%.
Launched Stelo, the first over-the-counter glucose biosensor in the U.S.
Advanced international product portfolio with launches of Dexcom G7 in Australia and Dexcom ONE+ in France.
DexCom
DexCom
DexCom Revenue by Segment
DexCom Revenue by Geographic Location
Forward Guidance
Dexcom is reiterating fiscal year 2024 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:
Positive Outlook
- Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth)
- Non-GAAP Gross Profit Margin of approximately 63%
- Non-GAAP Operating Margin of approximately 20%
- Adjusted EBITDA Margin of approximately 29%
Revenue & Expenses
Visualization of income flow from segment revenue to net income